|Articles|December 4, 2020

TB Vaccine Can Ease Course and Reduce Spread of COVID-19

Author(s)Killian Meara

Physicians are beginning to find key patterns which will aid public health in the future.

Early on in the current pandemic, there were active discussions on a connection between the coronavirus disease 2019 (COVID-19) and the vaccination against tuberculosis. Data showed that children who were vaccinated seemed to have a milder course of the disease. Now, a recent statistical analysis of data was conducted by investigators at St. Petersburg University to further investigate whether the bacilli Calmette-Guerin (BCG) vaccine could alter the course of COVID-19.

The BCG vaccine, a biological adjuvant, causes a complex response of both innate and cellular adaptive immunity. BCG serves as a trigger for an immune system response, which activates monocytes, macrophages and natural killer cells. These components contribute to the early activation of non-antigen-specific protective programs of the body to aid in the fight against a number of infections. One of the infections which the BCG can alter may be COVID-19.

The acute respiratory distress syndrome caused by COVID-19 is characterized by the triggering of inflammatory mediators like cytokines. After a BCG vaccine, lymphocytes produce Gamma-interferon, which modulates the activity of a number of interleukins, potentially weakening the course of COVID-19 by reducing the activity of IL-12 and IL-18 -dependent reactions.

The data revealed important information that showed an association between the course of acute interstitial pneumonia caused by the infection, the mortality rate and being vaccinated with the BCG vaccine.

In countries and areas where there was a national vaccine immunization program, especially with revaccination emphasized, there was an overall lower level of mortality rates. In countries where there were no large-scale vaccine programs or ones that had stopped for over 20 years, such as Italy, Germany and the United Sates, there were significantly higher rates of mortality.

“There is reason to believe that in adults and elderly people who were not vaccinated in early childhood, the effect of late vaccine administration will be significantly less,” Leonid Churilov, one of the lead investigators said. “At the same time, there are research papers by scientists from the Netherlands, where BCG is not given in childhood. They indicate that BCG administration to adults does not worsen, and perhaps, somewhat attenuates the course of the disease when infected with the new coronavirus.”


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.